Recent news coverage highlights UTMD's quarterly earnings declines year-over-year attributed to falling OEM sales, trade disruptions, and margin pressures. The company continues to maintain dividend payments with ex-dividend dates noted in market reports.

• Utah Medical's Q4 earnings were negatively impacted by a decline in OEM sales, resulting in a year-over-year decrease [N2].
• UTMD's Q3 earnings declined year-over-year due to trade disruptions and margin compression [N3].
• Q2 earnings slipped year-over-year attributed to falling OEM sales, with the stock down 3% following the report [N4].
• The company reported a Q2 decline consistent with prior reports of OEM sales challenges [N6].
• Q1 earnings dropped 16% year-over-year due to a sales slump, though the stock rose 1% after the announcement [N8].
• Market reports noted upcoming ex-dividend dates for UTMD among other stocks [N1].
• Daily dividend reports included UTMD, indicating ongoing dividend payments [N5].

UTMD benefits from a diversified product portfolio focused on critical care medical devices with established clinical benefits and trusted brand recognition. Its global distribution network and direct sales channels provide broad market access. The company's strong liquidity position and history of returning capital to shareholders through dividends and share repurchases reflect financial discipline. Continued product development and acquisitions support innovation and market relevance. The company's experienced workforce and manufacturing capabilities underpin consistent product quality and operational reliability.

UTMD faces competitive pressures from multiple medical device companies, with challenges in maintaining clinician access and influence in purchasing decisions, especially in the U.S. market where administrative focus on unit price may undermine the value of safety and clinical outcome improvements. Trade disruptions, tariffs, and foreign currency fluctuations impact cost competitiveness and sales, particularly in OEM and international markets. Declines in OEM sales and margin pressures have been reported in recent quarters. The company's reliance on a limited number of large OEM customers in the past, now reduced, highlights customer concentration risks. Regulatory and administrative burdens may delay new product introductions and limit market penetration.

UTMD's moat is based on its long-standing reputation for producing differentiated medical devices that improve patient safety and clinical outcomes, supported by decades of trusted use and strong brand recognition through trademarks. The company's integration of multiple engineering disciplines and manufacturing expertise enables it to deliver reliable, cost-effective solutions. Its direct relationships with clinicians and specialized sales force focused on clinical applications provide a competitive advantage in marketing and customer support. The company's global distribution network, including owned subsidiaries and numerous independent distributors, supports market reach. Additionally, UTMD's ISO 13485 certification and manufacturing capabilities for OEM customers contribute to operational strength. However, competition is significant with multiple competitors for each device type, and the company faces challenges from restricted clinician access and administrative purchasing processes in the U.S.

• Competitive and Market Access Risks: UTMD competes with multiple companies for each device type and relies heavily on clinician access for marketing. Increasing restrictions on clinician access and hospital purchasing decisions focused on price rather than clinical outcomes may weaken UTMD's competitive position.
• Trade and Currency Risks: The company is exposed to trade disruptions, tariffs, and foreign currency fluctuations that affect cost competitiveness and sales, especially in OEM and outside the U.S. markets.
• Customer Concentration and OEM Sales Decline: Significant decline and cessation of sales to a previously large OEM customer (PendoTECH) highlight risks related to customer concentration and reliance on OEM sales.
• Regulatory and Administrative Burdens: Lengthy and complex regulatory approval processes and administrative purchasing steps may delay or prevent new product introductions and market acceptance.

• Utah Medical Products, Inc. (UTMD) produces high-quality, cost-effective medical devices focused on safety and improved patient outcomes, primarily for critical care areas such as neonatal intensive care units (NICU), labor and delivery (L&D), and women's health centers in hospitals, as well as outpatient clinics and physician offices [S1].
• UTMD's business success depends on recognizing clinician and patient needs, rapid design or acquisition of economical solutions with regulatory approval, reliable manufacturing, and sales through direct channels or partnerships with companies that have distribution resources [S1].
• The company integrates multiple engineering disciplines including electronics, software, mechanical assembly, plastics processing, and instrumentation to create differentiated devices that improve patient safety, clinical outcomes, and reduce total cost of care [S1].
• UTMD sells domestically directly to clinical end-users or stocking distributors and manufactures components and finished devices on a subcontract basis for other medical device companies and other businesses [S1].
• Outside the U.S., UTMD sells directly to end-users in Canada, UK, France, Ireland, Australia, and New Zealand, and through approximately 200 independent distributors globally, with 108 distributors purchasing at least $5,000 in 2025 [S1].
• The company has a history of acquisitions and expansions including Columbia Medical, Gesco International neonatal product line, Abcorp, Femcare Holdings Ltd, and has established subsidiaries in Ireland, UK, Australia, Canada, and New Zealand to support manufacturing and distribution [S1].
• In 2025, sales from outside the U.S. represented 41% of consolidated revenues, with 72% of OUS sales invoiced in foreign currencies, exposing the company to foreign exchange risks [S1].
• UTMD's OEM sales channel involves selling components and finished devices to other companies; in 2025, OEM sales included 134 companies domestically, but the largest OEM customer PendoTECH's sales declined significantly and ceased after 1H 2025 [S1].
• The company maintains ISO 13485 certification, supporting its manufacturing quality and ability to serve OEM customers [S1].
• UTMD's product development focuses on improvements to existing devices, new devices with significant safety or cost benefits, and acquisitions or licensing of technology; internal product development expenses were about 2% of sales in 2026 [S1].
• The company employs approximately 140 full-time employees worldwide, with an average tenure of 17 years among Utah and Ireland employees, reflecting experienced staff critical for quality manufacturing and product knowledge [S1].
• UTMD owns seven unexpired U.S. patents and numerous trademarks, with trademarks considered more valuable due to brand recognition in the medical community [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents of $85.8 million, current assets of $97.7 million, current liabilities of $2.6 million, resulting in a current ratio of 37.62 and cash ratio of 33.01, indicating strong liquidity [S1].
• Net income for fiscal year 2025 was $2.57 million, with basic EPS of $3.48 and diluted EPS of $0.80 [S1].
• UTMD has returned $156 million to shareholders via share repurchases and $90 million in dividends since 1992 [S1].
• The company faces competitive pressures from multiple competitors for each device type, with competition based on improved patient safety and device reliability; access to clinicians for marketing is increasingly restricted in the U.S. [S1].
• UTMD's marketing includes direct sales representatives, independent consultants, and manufacturer representatives, focusing on clinical applications and customer training [S1].
• The company is affected by trade disruptions, tariffs, and foreign currency fluctuations impacting cost competitiveness and sales, especially in OEM and OUS markets [N2][N3][N4].
• Recent news reports indicate quarterly earnings declines year-over-year due to OEM sales declines, trade disruptions, and margin pressures [N2][N3][N4][N6][N8].
• The company maintains a dividend policy with ex-dividend dates noted in market reports [N1][N5].